Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective

Open access
TACK, J., FRIED, M., HOUGHTON, L. A., SPICAK, J., FISHER, G. · 2006 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Irritable bowel syndrome (IBS) is a common, chronic disorder, characterized by abdominal pain/discomfort, bloating and altered bowel habit. Aim: To conduct a systematic evidence‐based review of pharmacological therapies currently used, or in clinical development, for the treatment of IBS in Europe. The safety and tolerability of these therapies are the subject of an accompanying review. Methods: A literature search was completed for randomized controlled studies which included adult patients with IBS and an active or placebo control, assessed IBS symptoms, and were published in English between January 1980 and June 2005. The level of evidence for efficacy was graded according to the quality of the trial design and the study outcome. Results: There is some evidence for improvement of individual IBS symptoms with antidiarrhoeals (diarrhoea), antispasmodics (abdominal pain/discomfort), bulking agents (constipation), tricyclic antidepressants (abdominal pain/discomfort) and behavioural therapy. In contrast, there is strong evidence for the improvement of global IBS symptoms with two new serotonergic agents: the 5‐HT 4 selective agonist tegaserod (IBS with constipation) and the 5‐HT 3 antagonist alosetron (IBS with diarrhoea). Further data are required for the 5‐HT 3 antagonist, cilansetron, and the mixed 5‐HT 3 antagonist/5‐HT 4 agonist renzapride before their utility in IBS can be appraised. Conclusions: There is limited evidence for the efficacy, safety and tolerability of therapies currently available in Europe for the treatment of IBS. Overall, there is an absence of pharmacological agents licensed specifically for the treatment of IBS subtypes, and new agents are awaited in Europe that will allow changes in clinical practice to focus on and improve global IBS symptoms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2006.02938.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 131

  1. 10.1046/j.1365-2036.2003.01456.x · DOI · Paper page
  2. 10.1001/archinte.163.8.929 · DOI · Paper page
  3. Zacker C, 2004, Absenteeism among employees with irritable bowel syndrome, Manag Care Interface, 17, 28
  4. Smith GD, 2004, A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study, Br J Gen Pract, 54, 503
  5. 10.2165/00019053-200220070-00003 · DOI · Paper page
  6. Brandt LJ, 2002, Systematic review on the management of irritable bowel syndrome in North America, Am J Gastroenterol, 97, S7, 10.1016/S0002-9270(02)05657-5 · DOI · Paper page
  7. 10.1055/s-2002-22324 · DOI
  8. Kong SC, 2005, The incidence of self‐prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases, J Clin Gastroenterol, 39, 138
  9. 10.1097/00042737-200212000-00007 · DOI
  10. 10.1097/00042737-200410000-00008 · DOI
  11. 10.1002/pds.997 · DOI
  12. ACG, 2002, American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence‐based position statement on the management of irritable bowel syndrome in North America, Am J Gastroenterol, 97, S1, 10.1016/S0002-9270(02)05656-3 · DOI
  13. CPMP, 2003, Points to Consider on the Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome
  14. Wheatley D, 1976, Irritable colon syndrome treated with an anti‐spasmodic drug, Practitioner, 217, 276
  15. 10.1097/00004836-198106000-00009 · DOI
  16. 10.1136/bmj.1.6160.376 · DOI
  17. 10.1159/000199329 · DOI
  18. Tudor GJ, 1986, A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome, Br J Clin Pract, 40, 276, 10.1111/j.1742-1241.1986.tb07977.x · DOI
  19. Chapman ND, 1990, A comparison of mebeverine with high‐fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomized, parallel group study, Br J Clin Pract, 44, 461, 10.1111/j.1742-1241.1990.tb10058.x · DOI
  20. Awad R, 1995, Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double‐blind placebo‐controlled trial, Acta Gastroenterol Latinoam, 25, 137
  21. Baldi F, 1991, Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy, Ital J Gastroenterol Hepatol, 23, 60
  22. Villagrasa M, 1991, Aleatory clinical study comparing otilonium bromide with a fiber‐rich diet in the treatment of irritable bowel syndrome, Ital J Gastroenterol, 23, 67
  23. 10.1046/j.1365-2036.1998.00397.x · DOI
  24. 10.1097/00042737-200212000-00008 · DOI
  25. Ferrari A, 1986, Double‐blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome, Clin Ther, 8, 320
  26. Piai G, 1987, Long‐term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound, Curr Ther Res, 41, 967
  27. Centonze V, 1988, Oral cimetropium bromide, a new antimuscarinic drug, for long‐term treatment of irritable bowel syndrome, Am J Gastroenterol, 83, 1262
  28. 10.1136/gut.31.3.355 · DOI
  29. Fielding JF, 1980, Double blind trial of trimebutine in the irritable bowel syndrome, Ir Med J, 73, 377
  30. 10.1185/03007998009109464 · DOI
  31. Ghidini O, 1986, Single drug treatment for irritable colon: rociverine versus trimebutine maleate, Curr Ther Res, 39, 541
  32. Schaffstein W, 1990, Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome, Curr Ther Res, 47, 136
  33. 10.1007/BF02943704 · DOI
  34. Piai G, 1986, Treatment of irritable bowel syndrome, Clin Trials J, 23, 6
  35. 10.1016/S0210-5705(03)70470-1 · DOI
  36. Quartero A, 2005, Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome, Cochrane Database Syst Rev, CD003460
  37. 10.1111/j.1365-2036.2004.02267.x · DOI · Paper page
  38. 10.1111/j.1365-2036.1994.tb00322.x · DOI · Paper page
  39. 10.1016/S0140-6736(76)91402-1 · DOI
  40. 10.1016/S0140-6736(77)90605-5 · DOI
  41. 10.7326/0003-4819-95-1-53 · DOI
  42. Golechha AC, 1982, Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double‐blind crossover study), J Assoc Physicians India, 30, 353
  43. Arthurs Y, 1983, Double blind trial of ispaghula/poloxamer in the Irritable Bowel Syndrome, Ir Med J, 76, 253
  44. 10.3109/00365528509091653 · DOI
  45. 10.1136/gut.28.2.221 · DOI
  46. 10.1136/gut.28.11.1510 · DOI
  47. 10.1016/0016-5085(90)91292-E · DOI
  48. 10.1111/j.1440-1746.1990.tb01432.x · DOI
  49. 10.1111/j.1365-2036.1993.tb00074.x · DOI
  50. 10.1111/j.1365-2036.1994.tb00323.x · DOI
  51. 10.1016/0022-3999(92)90026-X · DOI
  52. 10.1159/000198701 · DOI
  53. 10.1016/j.nut.2004.05.016 · DOI
  54. 10.1177/146642400512500112 · DOI
  55. 10.1007/BF01296258 · DOI · Paper page
  56. 10.3109/00365528709091004 · DOI
  57. 10.3109/00365529609006766 · DOI · Paper page
  58. 10.3109/00365528709091003 · DOI · Paper page
  59. 10.1023/B:APBI.0000017861.60439.95 · DOI
  60. Halpern GM, 1996, Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double‐blind, cross‐over trial, Am J Gastroenterol, 91, 1579
  61. 10.1136/gut.24.12.1135 · DOI
  62. 10.1185/03007998009109491 · DOI
  63. 10.1016/S0033-3182(78)70930-8 · DOI
  64. 10.2190/WFHG-GR7T-79D6-UQVD · DOI
  65. 10.3109/00365528209181108 · DOI
  66. 10.1080/00365521.1984.12005817 · DOI
  67. 10.1007/BF01297051 · DOI · Paper page
  68. Vij JG, 1991, Effect of antidepressant drug (doxepin) on irritable bowel syndrome, Indian J Psychiatry, 33, 243
  69. 10.1111/j.1440-1746.1998.tb00723.x · DOI
  70. 10.1111/j.1572-0241.2004.04127.x · DOI · Paper page
  71. 10.1016/S1542-3565(03)70039-1 · DOI · Paper page
  72. 10.1016/S0016-5085(00)80649-6 · doi:10.1016/s0016-5085(00)80649-6
  73. 10.1046/j.1365-2036.2001.01094.x · DOI · Paper page
  74. 10.1046/j.1365-2036.2002.01372.x · DOI · Paper page
  75. 10.1136/gut.52.5.671 · DOI · Paper page
  76. Hämling J, 1998, Titration regimen indicates partial 5‐HT4 agonist HTF 919 improves symptoms of constipation predominant irritable bowel syndrome (C‐IBS), Digestion, 59, 735
  77. Lefkowitz MP, 1999, The 5‐HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS), Am J Gastroenterol, 94, 266
  78. Lefkowitz MP, 1999, Relief of overall GI symptoms and abdominal pain and discomfort as outcome measures in a clinical trial of irritable bowel syndrome with HTF 919, Gastroenterology, 116, A1027
  79. 10.1080/00365520310006748 · DOI
  80. Tack J, 2004, Tegaserod provides rapid and sustained relief of overall IBS symptoms and abdominal discomfort/pain when used as repeated treatment in women with IBS‐C, Gut, 53, A69
  81. 10.1111/j.1572-0241.2002.05692.x · DOI
  82. Schoenfeld P, 2002, Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta‐analysis of randomized controlled trials, Gastroenterology, 122, A46S
  83. 10.1053/gast.2001.21166 · DOI · Paper page
  84. 10.1159/000070202 · DOI
  85. 10.1517/14656566.4.11.2089 · DOI
  86. 10.1046/j.1365-2036.1996.30172000.x · DOI
  87. 10.1159/000201377 · DOI
  88. 10.1016/S0025-6196(12)60797-6 · DOI
  89. 10.1046/j.1365-2036.1999.00610.x · DOI · Paper page
  90. 10.1046/j.1365-2036.1999.00678.x · DOI
  91. 10.1016/S0140-6736(00)02033-X · DOI · Paper page
  92. 10.1111/j.1572-0241.2001.04128.x · doi:10.1111/j.1572-0241.2001.04128.x · Paper page
  93. 10.1046/j.1365-2036.2000.00684.x · DOI · Paper page
  94. 10.1001/archinte.161.14.1733 · DOI · Paper page
  95. 10.1111/j.1572-0241.2004.30509.x · DOI
  96. 10.1016/S1542-3565(04)00284-8 · DOI
  97. 10.1046/j.1365-2982.2003.00389.x · DOI · Paper page
  98. Bradette M, 2004, Cilansetron in irritable bowel syndrome with diarrhoea predominance (IBS‐D): efficacy and safety in a 6 month global study, Gastroenterology, 126, A42
  99. Coremans G, 2004, Cilansetron, a novel 5‐HT3 antagonist demonstrated efficacy in males with irritable bowel syndrome with diarrhoea‐predominance (IBS‐D), Gastroenterology, 126, A‐643
  100. 10.1097/00004836-199102000-00012 · DOI
  101. 10.1046/j.1365-2036.1997.133311000.x · DOI
  102. 10.1080/00365529850166833 · DOI
  103. 10.1080/00365529850171873 · DOI
  104. 10.1111/j.1440-1746.2004.03384.x · DOI
  105. Henderson JC, 2004, A phase IIb clinical study of renzapride in mixed‐symptom (alternating) irritable bowel syndrome, Gastroenterology, 126, A‐915
  106. Meyers N, 2004, Efficacy and safety of renzapride in patients with constipation‐predominant IBS: a Phase IIb study in the UK primary healthcare setting, Gastroenterology, 126, A‐640
  107. 10.1016/S1542-3565(04)00391-X · DOI
  108. 10.2165/00002018-200427040-00002 · DOI
  109. 10.1177/107424840200700202 · DOI
  110. 10.1016/S0140-6736(83)90678-5 · DOI · Paper page
  111. 10.1111/j.2044-8260.1985.tb01340.x · DOI
  112. 10.1016/S0005-7894(89)80130-3 · DOI
  113. 10.1016/0022-3999(91)90041-L · DOI
  114. Rumsey N, 1991, Towards Confident Management of Irritable Bowel Syndrome: Current Approaches, 33
  115. 10.1159/000200738 · DOI
  116. 10.1016/0005-7967(92)90141-3 · DOI
  117. 10.1007/BF00999789 · DOI
  118. 10.1192/bjp.163.3.315 · DOI
  119. 10.1037/0022-006X.62.3.576 · DOI · Paper page
  120. 10.1111/j.1572-0241.2000.01937.x · DOI · Paper page
  121. 10.1016/S0005-7894(98)80016-6 · DOI · Paper page
  122. 10.1097/01.psy.0000116964.76529.6e · DOI · Paper page
  123. 10.1007/s003840000248 · DOI
  124. 10.1046/j.1365-2036.2002.01320.x · DOI
  125. 10.1007/BF02209014 · DOI
  126. 10.1053/cgh.2003.50019 · DOI
  127. Pimentel M, 2003, Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double‐blind, randomized, placebo‐controlled study, Am J Gastroenterol, 98, 412
  128. 10.1007/BF02936952 · DOI · Paper page
  129. 10.1001/jama.280.18.1585 · DOI · Paper page
  130. 10.1111/j.1365-2036.2005.02330.x · DOI
  131. 10.1097/01.mcg.0000139029.00451.c7 · DOI

Cited by

See all 169

Metadata

Authors
TACK, J., FRIED, M., HOUGHTON, L. A., SPICAK, J., & FISHER, G.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2006-06-26
Volume
24
Issue
2
Pages
183-205
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2060809912
Cited by
169
References
16
FWCI
2.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective. https://app.cochat.ai/papers/10.1111/j.1365-2036.2006.02938.x
The paper
TACK, J., FRIED, M., HOUGHTON, L. A., SPICAK, J., & FISHER, G. (2006). Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.02938.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.